19,897 Shares in Kenvue Inc. (NYSE:KVUE) Purchased by Gentry Private Wealth LLC

Gentry Private Wealth LLC acquired a new position in Kenvue Inc. (NYSE:KVUE) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 19,897 shares of the company’s stock, valued at approximately $362,000.

A number of other large investors have also added to or reduced their stakes in the company. Manchester Capital Management LLC raised its holdings in Kenvue by 80.8% in the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after purchasing an additional 530 shares in the last quarter. Tradition Wealth Management LLC increased its holdings in shares of Kenvue by 2.8% during the fourth quarter. Tradition Wealth Management LLC now owns 21,278 shares of the company’s stock valued at $458,000 after acquiring an additional 575 shares in the last quarter. MV Capital Management Inc. increased its holdings in shares of Kenvue by 71.2% during the first quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock valued at $33,000 after acquiring an additional 642 shares in the last quarter. Royal Capital Wealth Management LLC increased its holdings in shares of Kenvue by 2.3% during the fourth quarter. Royal Capital Wealth Management LLC now owns 29,746 shares of the company’s stock valued at $640,000 after acquiring an additional 673 shares in the last quarter. Finally, Cove Private Wealth LLC increased its holdings in shares of Kenvue by 1.6% during the second quarter. Cove Private Wealth LLC now owns 44,539 shares of the company’s stock valued at $810,000 after acquiring an additional 700 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Up 1.6 %

Shares of KVUE opened at $22.86 on Friday. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $23.00. The company has a market capitalization of $43.77 billion, a PE ratio of 29.31, a price-to-earnings-growth ratio of 2.76 and a beta of 1.38. The stock has a fifty day simple moving average of $19.92 and a two-hundred day simple moving average of $19.67. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. The firm had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The company’s quarterly revenue was down .3% on a year-over-year basis. During the same period last year, the company earned $0.32 EPS. As a group, equities analysts forecast that Kenvue Inc. will post 1.08 EPS for the current year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 28th. Investors of record on Wednesday, August 14th were given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.59%. This is an increase from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date was Wednesday, August 14th. Kenvue’s dividend payout ratio (DPR) is presently 105.13%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Citigroup dropped their target price on Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. Royal Bank of Canada restated an “outperform” rating and issued a $24.00 price objective on shares of Kenvue in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft upped their price objective on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. UBS Group upped their price objective on Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. upped their price objective on Kenvue from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.